• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Voice Preservation

A person’s voice is part of their identity. It carries personality, humour, and emotion, and it is how most people connect with family and friends. Most people living with ALS/MND will lose some or all of their ability to speak.

Voice preservation means recording your voice so that a communication device can later speak in a voice that sounds like you. This page explains the options, when to start, and how to get support.

On this page

When to start  │  Your options  │  Getting started  │  Free voice cloning  │  Why it matters  │  Alliance position  │  Resources

Start early, while your voice is clear

Voice preservation works best when recordings are made early, while speech is still clear. Talk to a speech-language pathologist soon after diagnosis, even if your speech has not changed.

If your voice has already started to change, options may still be available, including using older recordings. Recording can be tiring, so spread it over several short sessions.

Voice preservation is a personal choice. Some people prefer to use a standard computer voice, and that is also a good option.

Voice preservation options

There are three main approaches to preserving a voice. They work differently and can be used together.

Message banking

Message banking records words and phrases exactly as you say them. These can be everyday phrases, such as “Hello, how are you?”, or personal ones: terms of endearment, favourite sayings, a laugh, or calling a pet. When played back on a device, they sound exactly as recorded, with your own tone and emotion. Recorded messages cannot be changed or used to create new sentences.

Voice banking

Voice banking records you reading a set list of sentences. Software uses these recordings to create a synthetic version of your voice. A communication device can then say anything you type, in a voice similar to your own.

Voice cloning

Voice cloning uses artificial intelligence to create a realistic copy of your voice from recordings. Some services can also work from existing audio, such as videos or voice messages. Like voice banking, a cloned voice can say anything you type on a communication device.

Many people combine approaches. Message banking keeps the phrases that matter most, with their original tone and emotion, while a banked or cloned voice can be used to say anything else.

Getting started

  • Ask your speech-language pathologist or ALS/MND clinic about the options available where you live
  • Check which options work with your current or future communication device
  • Ask about costs and funding, which vary between countries and services
  • Ask family and friends which of your phrases and sayings they would most like to keep

Free AI voice cloning through ElevenLabs

ElevenLabs logo

Through the ElevenLabs Impact Program, anyone living with ALS/MND, anywhere in the world, can access a free Pro voice clone licence. A voice clone is a personalized AI replica of your own voice that can be added to a communication device and used to speak on your behalf.

Getting started takes three steps:

  1. Create your ElevenLabs account through the Impact Program.
    • Watch the step-by-step video tutorial
    • Download the application guide
  2. Record or upload audio files of your voice.
  3. Add your voice clone to your communication device.

Why voice preservation matters

Orlando Ruiz, founder of the Asociación Colombiana de ELA (ACELA) and a person living with ALS/MND, explains what losing your voice means, and how voice preservation can protect dignity, independence, and identity.

Alliance position

Voice preservation should be available to everyone who needs it. The Alliance believes every person living with ALS/MND should be able to access voice preservation at diagnosis, wherever they live.

Voice preservation is not designed, intended, or made available for the diagnosis, treatment, or prevention of disease, or for use as a medical device. It is not a substitute for professional medical advice, diagnosis, treatment, or judgment.


Resources from our members

Explore additional resources about voice banking, message banking, and voice cloning developed by Alliance member associations.

Voice Banking and Message Banking

MND Association · English

Information about how voice banking and message banking work, how to bank your voice, and where to find support.

View resource →

MND and Communication

Irish Motor Neurone Disease Association · English

Information about message banking, voice banking, and voice cloning, including the Irish Message Banking Project.

View resource →

Primary Sidebar

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Liam Dwyer, England

    Liam Dwyer, England

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Anna Barrow, UK

    Anna Barrow, UK

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Jo Knowlton, Scotland

    Jo Knowlton, Scotland

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Jean Waters, UK

    Jean Waters, UK

  • Hollister

    Hollister
    hollister

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Len Johnrose, England

    Len Johnrose, England

  • JP

    JP

  • Diana Fernandez, Argentina

    Diana Fernandez, Argentina

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Mike Small, UK

    Mike Small, UK

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • John Dinon, Australia

    John Dinon, Australia

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Francisco Perez Palop, Spain

    Francisco Perez Palop, Spain

  • Kirsty Gerlach, New Zealand

    Kirsty Gerlach, New Zealand

  • Bob Simonds, USA

    Bob Simonds, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login